Total Payments
$438,963
2024 Payments
$9,263
Companies
20
Transactions
422
Medicare Patients
129
Medicare Billing
$10,323
Payment Breakdown by Category
Consulting$224,347 (51.1%)
Other$165,146 (37.6%)
Travel$29,286 (6.7%)
Food & Beverage$9,877 (2.3%)
Education$5,807 (1.3%)
Research$4,500 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $224,347 | 90 | 51.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,546 | 93 | 37.5% |
| Travel and Lodging | $29,286 | 101 | 6.7% |
| Food and Beverage | $9,877 | 131 | 2.3% |
| Education | $5,807 | 4 | 1.3% |
| Unspecified | $4,500 | 2 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $600.00 | 1 | 0.1% |
Payments by Type
General
$434,463
420 transactions
Research
$4,500
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $93,172 | 128 | $0 (2019) |
| Mylan Specialty L.P. | $73,010 | 100 | $0 (2020) |
| PneumRx, Inc | $66,274 | 23 | $0 (2019) |
| Grifols USA, LLC | $41,239 | 51 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $29,438 | 23 | $0 (2020) |
| AstraZeneca UK Limited | $25,227 | 16 | $0 (2024) |
| Insmed, Inc. | $21,040 | 12 | $0 (2024) |
| Mylan Inc. | $10,780 | 6 | $0 (2023) |
| Novartis Pharma AG | $10,293 | 6 | $0 (2018) |
| UCB SA | $9,800 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,263 | 6 | AstraZeneca UK Limited ($5,423) |
| 2023 | $14,929 | 10 | Insmed, Inc. ($7,200) |
| 2022 | $37,261 | 19 | Chiesi USA, Inc. ($8,125) |
| 2021 | $26,127 | 18 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,930) |
| 2020 | $33,390 | 30 | Mylan Specialty L.P. ($16,203) |
| 2019 | $136,940 | 163 | GlaxoSmithKline, LLC. ($60,192) |
| 2018 | $123,243 | 103 | PneumRx, Inc ($46,754) |
| 2017 | $57,810 | 73 | PneumRx, Inc ($11,884) |
All Payment Transactions
422 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,556.00 | General |
| Category: Respiratory | ||||||
| 05/16/2024 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 04/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,167.00 | General |
| Category: Respiratory | ||||||
| 01/11/2024 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 11/18/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 10/13/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 10/10/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $778.00 | General |
| Category: Respiratory | ||||||
| 06/30/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| 06/01/2023 | Grifols Shared Services North America, Inc. | Prolastin-C Liquid (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $820.00 | General |
| Category: Pulmonology | ||||||
| 04/21/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 03/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,556.00 | General |
| Category: Respiratory | ||||||
| 03/06/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Respiratory | ||||||
| 03/01/2023 | Mylan Inc. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,175.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 01/05/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 11/03/2022 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,665.00 | General |
| Category: Pulmonology | ||||||
| 11/03/2022 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $164.26 | General |
| Category: Pulmonology | ||||||
| 11/03/2022 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Travel and Lodging | Cash or cash equivalent | $65.00 | General |
| Category: Pulmonology | ||||||
| 09/19/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $2,836.00 | General |
| 09/14/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,556.00 | General |
| Category: Respiratory | ||||||
| 09/02/2022 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| 07/12/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 07/12/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 07/12/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CFOR258D2416 | Novartis Pharma AG | $3,700 | 1 |
| NONE | Chiesi USA, Inc. | $800.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 37 | 41 | $11,520 | $2,600 |
| 2021 | 1 | 57 | 74 | $20,380 | $5,431 |
| 2020 | 1 | 35 | 43 | $11,204 | $2,292 |
Total Patients
129
Total Services
158
Medicare Billing
$10,323
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 41 | $11,520 | $2,600 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 57 | 74 | $20,380 | $5,431 | 26.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 43 | $11,204 | $2,292 | 20.5% |
About Dr. James Donohue, MD
Dr. James Donohue, MD is a Pulmonary Disease healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740353556.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Donohue, MD has received a total of $438,963 in payments from pharmaceutical and medical device companies, with $9,263 received in 2024. These payments were reported across 422 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($224,347).
As a Medicare-enrolled provider, Donohue has provided services to 129 Medicare beneficiaries, totaling 158 services with total Medicare billing of $10,323. Data is available for 3 years (2020–2022), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Chapel Hill, NC
- Active Since 11/17/2006
- Last Updated 10/02/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1740353556
Products in Payments
- Yupelri (Drug) $71,753
- PNEUMRX COILS (Device) $66,415
- TRELEGY ELLIPTA (Drug) $33,400
- NUCALA (Biological) $21,516
- Prolastin-C Liquid (Biological) $20,739
- Prolastin-C (Biological) $17,892
- ANORO (Drug) $13,864
- FASENRA (Biological) $8,700
- BREZTRI (Drug) $7,780
- QVA149A (Drug) $6,593
- SPIRIVA (Drug) $4,930
- BREZTRI AEROSPHERE (Drug) $4,767
- Wixela Inhub (Drug) $4,375
- FOR258D (Drug) $3,700
- NIOX VERO DEVICE (Device) $3,679
- STIOLTO (Drug) $2,636
- MK-7264 (Drug) $2,625
- TUDORZA PRESSAIR (Drug) $2,423
- SYMBICORT (Drug) $2,334
- FASENRA (Drug) $1,556
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chapel Hill
Dr. Michael Knowles, Md, MD
Pulmonary Disease — Payments: $73,864
Pulmonary Disease $73,864
Dr. Scott Donaldson, Md, MD
Pulmonary Disease — Payments: $62,208
Pulmonary Disease $62,208
Dr. Richard Boucher, Md, MD
Pulmonary Disease — Payments: $25,071
Pulmonary Disease $25,071
Dr. Peadar Noone, Md, MD
Pulmonary Disease — Payments: $16,919
Pulmonary Disease $16,919
Barbara Levarge, M.d, M.D
Pulmonary Disease — Payments: $8,563
Pulmonary Disease $8,563
Dr. Ashley Henderson, Md, MD
Pulmonary Disease — Payments: $7,890
Pulmonary Disease $7,890